Is Gilead Headed Lower From Here?
Merrill Lynch recently updated its view on Gilead Sciences, maintaining its Underperform rating for the stock but raising its price objective
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 260Health Insurance Mergers Falling Into Place
Over the long weekend, the first move toward an acquisition was made in the health insurance industry.
Implant Maker ConforMIS Jumps a Third on IPO
ConforMIS shares began trading Wednesday morning at $18 and popped to a high of $20.42 before pulling back.
IPO of Zynerba Pharmaceuticals Targets Cannabinoid Therapeutics
Zynerba Pharmaceuticals has filed with the U.S. Securities and Exchange Commission for its initial public offering (IPO).
Atara Biotherapeutics Files for IPO
Atara Biotherapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Teladoc Debuts Strong in IPO
Teladoc was set to be the first initial public offering (IPO) of its kind. The company claims to be the first and largest telehealth provider in the nation.
What Celgene Now Means for Juno
Celgene and Juno Therapeutics are coming together in a global collaboration for the development and commercialization of immunotherapies.
Sarepta Takes Its Foot off the Gas
Sarepta Therapeutics announces the completion of the rolling submission of a New Drug Application to the FDA for eteplirsen.
Do Health Insurance Mergers Really Need to Sweat DOJ Reviews?
The U.S. Department of Justice is now said to be set to give a very close review of any of the proposed mergers of the top health insurance players in America.
Is Big Pharma Advertising Getting Out of Control?
How much are big pharmaceutical companies really spending to get their drugs out there in the public eye?
Are Cancer Drugs Becoming Too Costly for Their Effectiveness?
When the American Society of Clinical Oncology (ASCO) decided to create a rating scale for cancer drugs, it certainly must have expected to get some pushback.
Can Celladon Weather the Storm?
Celladon is continuing to seek out a merger partner, and at the same time, it is not pursuing the further development of its existing programs.
CAR T-Cell Stocks a Better Way to Leverage Biotech Than New 3x ETFs
If you missed the biotech run and want to try to catch the train this late in the game, it would be wise not to use the new Proshares leveraged biotech ETFs.
Short Sellers Become More Focused on Big Pharma
The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Short Sellers Get More Selective on Big Biotech
The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech stocks was mixed.